Results 21 to 30 of about 8,134 (194)
Preclinical efficacy of [V 4 Q 5 ]dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer [PDF]
, 2018 Purpose Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V 4 Q 5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors.
Alonso, Daniel Fernando +6 more
core +1 more source
Tolvaptan induces body fluid loss and subsequent water conservation in normal rats
Journal of Pharmacological Sciences, 2022 We have recently reported that the urea osmolyte-associated water conservation system is activated in fluid loss models such as high salt-induced natriuresis, renal injury-induced impaired renal concentrating ability, or skin barrier dysfunction-induced ...
Satoshi Kidoguchi +6 more
doaj +1 more source
Effectiveness of Tolvaptan Treatment in Hyponatremic Patients
Turkish Journal of Internal Medicine, 2020 Objective: Non-peptide vasopressin receptor antagonists (vaptans) are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients.
Mehmet Fethullah Aydın +4 more
doaj +1 more source
Patient Preference and Adherence, 2021 Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H +3 more
doaj
European Journal of Histochemistry, 2022 Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan +4 more
doaj +1 more source
Improving Postdischarge Outcomes in Acute Heart Failure [PDF]
, 2018 The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P. +8 more
core +1 more source
International Journal of Cardiology: Heart & Vasculature, 2018 Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification ...
Shinichi Nonin +9 more
doaj +1 more source
A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. [PDF]
, 2018 Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD); however, the natural course of disease progression is heterogeneous between patients.
Bennett Wilton, Hayley +9 more
core +5 more sources
Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats
Journal of Pharmacological Sciences, 2013 Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure.
Takanori Yamazaki +10 more
doaj +1 more source
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
Therapeutic Advances in Endocrinology and Metabolism, 2023 The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Ploutarchos Tzoulis +4 more
doaj +1 more source